CLINICAL TRIALS PROFILE FOR ESTRADIOL CYPIONATE
✉ Email this page to a colleague
All Clinical Trials for ESTRADIOL CYPIONATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00870220 ↗ | Initiating Transdermal Estradiol Therapy in Turner's Syndrome | Terminated | Johns Hopkins University | Phase 1 | 2009-04-01 | This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. |
| NCT00870220 ↗ | Initiating Transdermal Estradiol Therapy in Turner's Syndrome | Terminated | Massachusetts General Hospital | Phase 1 | 2009-04-01 | This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. |
| NCT00870220 ↗ | Initiating Transdermal Estradiol Therapy in Turner's Syndrome | Terminated | Novo Nordisk A/S | Phase 1 | 2009-04-01 | This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. |
| NCT00870220 ↗ | Initiating Transdermal Estradiol Therapy in Turner's Syndrome | Terminated | Thomas Jefferson University | Phase 1 | 2009-04-01 | This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. |
| NCT00870220 ↗ | Initiating Transdermal Estradiol Therapy in Turner's Syndrome | Terminated | University of Michigan | Phase 1 | 2009-04-01 | This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ESTRADIOL CYPIONATE
Condition Name
Clinical Trial Locations for ESTRADIOL CYPIONATE
Trials by Country
Clinical Trial Progress for ESTRADIOL CYPIONATE
Clinical Trial Phase
Clinical Trial Sponsors for ESTRADIOL CYPIONATE
Sponsor Name
